Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

Biotech's Redemption Chance: Make Drugs, Foster Community

Jan. 17, 2006

By Cynthia Robbins-Roth

Biotech & Business Ethics: Time To Face Up To Reality

Dec. 12, 2005

By Cynthia Robbins-Roth

Biotech & Business Ethics: Time To Face Up To Reality

Dec. 12, 2005

By Cynthia Robbins-Roth

For All Biotech's Forward Progress, Issues Remain

Nov. 4, 2005

By Cynthia Robbins-Roth

For All Biotech's Forward Progress, Issues Remain

Nov. 4, 2005

By Cynthia Robbins-Roth

Pricing, Data Leaks, Safety: Biotech's Simmering Stew

Nov. 3, 2005

By Cynthia Robbins-Roth

Pricing, Data Leaks, Safety: Biotech's Simmering Stew

Nov. 3, 2005

By Cynthia Robbins-Roth

Australian Biotechs Should Rethink Financing Structure

Sep. 28, 2005

By Cynthia Robbins-Roth

Australian Biotechs Should Rethink Financing Structure

Sep. 28, 2005

By Cynthia Robbins-Roth

The List: Innovative Models On Which To Build Biotech

Aug. 3, 2005

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...